Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous Transplant

Inclusion Criteria: * Patients with confirmed multiple myeloma * Eligible for treatment with high dose melphalan based regimen and autologous peripheral stem cell transplant Exclusion Criteria: * Pregnant or lactating woman, as evaluated by serum testing within 24 hours of administration of the first vaccine * HIV infection confirmed by nucleic acid testing (NAT), as evaluated during pre transplant testing * Common variable immunodeficiency or other inherited systemic immunodeficiency syndrome * Active central nervous system (CNS) malignancy * Prior malignancy within 5 years of enrollment excluding non-melanoma skin cancer or cervical carcinoma after curative resection, not requiring chemotherapy. * History of severe allergy (e.g., anaphylaxis) to any component of pneumococcal conjugate vaccine 7 (PCV7), PCV13, or any diphtheria-toxoid containing vaccine. * Inclusion on a separate trial in which patients may be randomized or otherwise started on maintenance chemotherapies within the first 3 months of autologous transplantation * Patients with significant psychiatric illness likely to affect compliance, as determined by the treating physician * Active or uncontrolled infection * Diffusing lung capacity oxygenation (DLCO) \<50 % * Left ventricular ejection fraction (LVEF) \<40% * Bilirubin \>2